Research groups
Dr Sophie Binks
Clinical Lecturer
Honorary Neurology SpR
Brief biography
I
After a career in medical communications, I retrained in medicine and graduated with distinction and first in my cohort from Brighton & Sussex Medical School in 2013 (Professor Alasdair Smith prize for best performance in the overall programme), being awarded 18 prizes/scholarships during my medical degree, including three-times recipient of the Dean’s prize for best overall performance (years 1, 2 & 4). I completed a fellowship in autoimmune neurology in Oxford in 2016-2017 and was awarded my DPhil in neuroimmunology from the University of Oxford in 2022. In my current role, I work as a clinician-scientist and early career researcher at NDCN and the John Radcliffe Hospital, Oxford. My research programme focuses on clinical and genetic aspects of autoimmune encephalitis (AE). Significant breakthroughs I have published include human leucocyte antigen genetics (2018) and additional genetic risk loci (2025) in AE associated with antibodies to leucine-rich glioma-inactivated 1 (LGI1-Ab-E) and contactin-associated protein 2 (CASPR2). I have also been at the forefront of describing the impact of fatigue and quality of life outcomes in LGI1-Ab-E (2021 and 2024), and a unique naturally-occurring animal model of LGI1-Ab-E in pet cats (2025). As a thought leader in this field, I am active as an international speaker and educator, including supervision of postgraduate students, patient engagement activities, and professional leadership roles.
Key publications
-
Novel risk loci in LGI1-antibody encephalitis: genome-wide association study discovery and validation cohorts
Journal article
Binks SNM. et al, (2025), Brain, 148, 737 - 745
-
Residual Fatigue and Cognitive Deficits in Patients After Leucine-Rich Glioma-Inactivated 1 Antibody Encephalitis.
Journal article
Binks SNM. et al, (2021), JAMA neurology, 78, 617 - 619
-
Distinct HLA associations of LGI1 and CASPR2-antibody diseases
Journal article
Binks S. et al, (2018), Brain, 141, 2263 - 2271
-
LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes
Journal article
Binks SNM. et al, (2018), Journal of Neurology, Neurosurgery & Psychiatry, 89, 526 - 534
-
Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial.
Journal article
Chan D. et al, (2017), The Lancet. Neurology, 16, 591 - 600
Recent publications
-
The gut microbiome associated with LGI1‐antibody encephalitis
Journal article
Gilbert E. et al, (2025), Epilepsia
-
Distinctive seizure signature in the first video case-control study of a naturally-occurring feline autoimmune encephalitis model.
Journal article
Binks SNM. et al, (2025), Brain, behavior, and immunity, 126, 289 - 296
-
Capturing what matters: Patient‐reported LGI1‐ANTibody encephalitis outcome RatiNg scale (LANTERN)
Journal article
Kelly MJ. et al, (2025), Annals of Clinical and Translational Neurology, 12, 821 - 831
-
Novel risk loci in LGI1-antibody encephalitis: genome-wide association study discovery and validation cohorts
Journal article
Binks SNM. et al, (2025), Brain, 148, 737 - 745
-
Clinical data and reporting quality in NMDAR-antibody encephalitis and pregnancy: a systematic review
Journal article
Harris SL. et al, (2025), BMJ Neurology Open, 7, e001005 - e001005